文献速递淋巴瘤

慢性淋巴细胞白血病微小残留病分析:实现更个体化治疗的途径

Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
PubMed 文献 · Leukemia · 2018-03-26

慢性淋巴细胞白血病(CLL)治疗已发生显著变化,微小残留病(MRD)定量被证实为无进展生存和总生存的独立预后因素。欧洲CLL研究倡议(ERIC)与美国及澳大拉西亚合作者共同开发了可重复应用的统一检测方法,用于比较不同治疗的疗效。监管机构认可MRD分析可在达到生存终点前识别最有效治疗,欧洲已批准其作为随机研究许可的中间终点。随着BCL2通路抑制剂等治疗进展,MRD分析可能对多数患者和临床试验提供信息,有望成为临床实践中管理CLL患者的工具。

要点

  • MRD定量是CLL无进展生存和总生存的独立预后因素。
  • ERIC与美国及澳大拉西亚合作者开发了可重复应用的统一MRD检测方法。
  • 欧洲监管机构已批准MRD作为随机研究的许可中间终点。

核心结论

  • CLL的MRD评估已成为临床研究和开发不可或缺的工具,有望改变未来患者管理方式。

研究设计与样本

  • 综述,由欧洲CLL研究倡议(ERIC)与美国及澳大拉西亚合作者共同阐述CLL中MRD分析相关进展。

主要发现

  • MRD定量被证实为CLL无进展生存和总生存的独立预后因素。
  • ERIC与美国及澳大拉西亚合作者开发的统一检测方法可重复应用于比较不同治疗的疗效。
  • 监管机构认可MRD分析可在达到生存终点前识别最有效治疗,欧洲已批准其作为随机研究许可的中间终点。
  • 随着BCL2通路抑制剂等治疗进展,MRD分析可能对多数患者和临床试验提供信息。
  • 已认识到不同治疗类型需考虑MRD检测方法类型、最适评估时机和 compartment,以将残留病清除至低于指南阈值万分之一。

关键数值与推荐

  • 指南阈值:万分之一(one cell in ten thousand)。

临床怎么用

  • MRD分析有望成为临床实践中管理CLL患者的工具,并已成为临床研究和开发不可或缺的工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic approaches for chronic lymphocytic leukemia (CLL) have dramatically changed over the recent past. In parallel, quantification of minimal residual disease (MRD) proved to be an independent prognostic factor for progression-free and overall survival. The European Research Initiative on CLL (ERIC) in collaboration with American and Australasian partners developed harmonised assays that could be applied reproducibly to compare the efficacy of different treatments. The potential for MRD analysis to identify the most effective treatments prior to reaching survival endpoints was recognised by regulatory agencies and approved as an intermediate endpoint for licensure in randomized studies, in Europe. More recently treatment approaches have evolved, in particular with BCL2-pathway inhibitors, so that MRD analysis may be informative for most patients and clinical trials, potentially becoming a tool for managing CLL patients in clinical practice. In the recent past the importance of the type of MRD assay used, the most appropriate timing and compartment to assess for different treatment types have been learnt as we move towards eradicating residual disease beyond the guideline threshold of one cell in ten thousand. Nowadays, MRD assessment in CLL has quickly become an indispensable tool for clinical research and development that promise to change the way we manage our patients in the future.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ghia P, Rawstron A. Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. Leukemia. 2018. PMID: 29700386. doi:10.1038/s41375-018-0109-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。